Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02703779
Title Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Kansas Medical Center
Indications

multiple myeloma

Therapies

Bortezomib

Filgrastim + Plerixafor

Age Groups: adult
Covered Countries USA


No variant requirements are available.